Kura Oncology, Inc. · NASDAQ:KURA
Kura Oncology — Investor Presentation (August 2015)
26 slides from Kura Oncology's investor presentation, Aug 11, 2015
Slide 1: Kura Oncology Corporate Presentation, August 2015
Troy Wilson, Ph.D., J.D. President and Chief Executive Officer August 2015 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research and clinical development plans and projected timelines for tipifarnib, and our other programs, plans regarding regulatory filings, our
Slide 3: Investment summary
Investment summary Develop a diverse pipeline of targeted therapeutics for solid tumors and blood cancers Utilize precision medicine approach to identify patients most likely to benefit from treatments Strategy Development Approach Pipeline Solid Financials Fast-to-market strategies in select patien
Slide 4: Diverse Development Pipeline
Diverse Development Pipeline CANDIDATE LEAD OPTIMIZATION PRECLINICAL PHASE 1 PHASE 2 Milestones Tipifarnib Farnesyl Transferase Inhibitor Initiated May 2015 Phase 2 initiation anticipated Q3 2015 KO-947 ERK inhibitor IND anticipated 1H 2016 Menin- MLL inhibitor Development candidate anticipated 2H 2
Slide 5: Tipifarnib – Lead Product Candidate
Tipifarnib – LEAD Product CANDIDATE Licensed worldwide rights in oncology from Janssen; subject to ROFN Broad development program preceded advent of precision medicine; biomarker-based patient selection Studied in > 5,000 patients across a diverse range of solid and liquid tumors Generally well-tole
Slide 6: HRAS Mutations Are Enriched in Tumors
HRAS Mutations ARE Enriched in Tumors TISSUE HRAS MUTATION FREQUENCY Salivary gland 15% Urinary tract 11% Cervix 9% Upper aerodigestive tract 9% Prostate 6% Skin 6% Stomach 4% Testis 4% Thyroid 3% Endocrine 3% Bone 2% Thymus 2% Y. Pylayeva-Gupta, E. Grabocka & D. Bar-Sagi, Nature Reviews Cancer 2011
Slide 7: Tipifarnib is active in patient-derived models of HRAS mutant tumors
Tipifarnib is active in patient-derived models of HRAS mutant Tumors Tipifarnib is active and selective in patient-derived xenograft (PDX) models of HRAS mutant tumors; minimal activity in non-HRAS tumors (bottom panel) No approved drugs currently indicated to treat HRAS mutant tumors
Slide 8: Tipifarnib: ongoing Phase 2 study in HRAS mutant solid tumors
Tipifarnib: ongoing Phase 2 study in HRAS mutant solid tumors Single arm, open-label, multi-centered study Primary Endpoint: ORR measure by RECIST v1.1 criteria Two patient cohorts Cohort 1: Thyroid tumors with documented HRAS mutations (n=18) Cohort 2: Solid tumors with documented HRAS mutations (n
Slide 9: High Phase 2 Activity of Tipifarnib in T-Cell Lymphomas
High Phase 2 Activity of Tipifarnib Has Been Demonstrated in T-Cell Lymphomas Previous Phase 2 trial in relapsed/refractory lymphomas conducted at Mayo Clinic and U. Iowa High activity demonstrated in heavily pretreated patients with T-Cell and Hodgkin’s Lymphoma1 ORR: 31% Disease Indication n CR n
Slide 10: Tipifarnib – Visual examples of lesion clearing
Tipifarnib – Visual examples of lesion clearing Witzig T. et al. Blood. 2011; 118:4882-9, Ding H. et al. Blood. 2011; 118:4872-81. Subcutaneous Panniculitis-like T-Cell Lymphoma (SPTCL) Mycosis Fungoides (CTCL) On Study After 2 months After 3 months On Study After 9 months
Slide 11: Tipifarnib Shows Encouraging Activity relative to Approved Agents in PTCL
Tipifarnib Shows Encouraging Activity relative to Approved Agents in Relapsed/Refractory PTCL N Objective Response Rate (%) Median PFS / TTP (months) Median OS (months) 1201,2 26 1.6 7.9 1301,2 25 4.0 11.3 1091,2 27 3.5 14.5 Tipifarnib (T-cell / Hodgkin’s Lymphoma) 363 31 (including 3 CRs and 1 PR i
Slide 12: Tipifarnib: Planned Phase 2 study in PTCL
Tipifarnib: Planned Phase 2 study in PTCL Single arm, open-label, multi-centered study Primary Endpoint: ORR measure by International Workshop Criteria Single patient cohort of n=18; potential for expansion to n=30 Milestones Planned start in Q3 2015 Topline data expected 1H 2017 If positive, potent
Slide 13: Tipifarnib phase 2 trials
Tipifarnib phase 2 trials Ongoing Phase 2 study in HRAS mutant tumors Planned Phase 2 study in Peripheral T-Cell Lymphoma Potential to support single-arm pivotal trials Evaluating additional indications for both company-sponsored and investigator-sponsored studies Development Plans Anticipated Miles
Slide 14: Preclinical ERK inhibitor – KO-947
Preclinical erk inhibitor – ko-947 Discovered and developed by Kura Oncology team at Araxes/Wellspring; acquired through asset purchase ATP active-site inhibitor of ERK Targets well-validated pathway that has led to multiple approved targeted oncology agents Aberrant signaling caused by activating m
Slide 15: KO-947 Potently Inhibits Growth of Cell Lines with BRAF, NRAS and KRAS Mutations
KO-947 Potently Inhibits Growth of Cell Lines with BRAF, NRAS and KRAS Mutations KO-947 is more potent than Merck (SCH-772984) and Genentech (GDC-0994) compounds in cell lines with MAPK pathway activation due to BRAF, NRAS and KRAS mutations KO-947 is less active in non-MAPK activated cell lines
Slide 16: KO-947 Displays Strong Activity in BRAF Mutant Melanoma Models
KO-947 DISPLAYS STRONG ACTIVITY IN BRAF MUTANT MELANOMA MODELS KO-947 shows activity in melanoma cells with BRAF or NRAS mutations that are resistant to treatment with BRAF or MEK inhibitors IC50 (nM) A375 NRAS V600E Vemurafenib 4,200 > 10,000 > 10,000 Trametinib 7 77 300 GDC-0994 285 890 760 KO-947
Slide 17: KO-947 Displays Anti-Tumor Activity in KRAS Mutant NSCLC Tumor Models
KO-947 Displays Anti-Tumor Activity in KRAS Mutant NSCLC Tumor Models KO-947 induced regression at 180 mg/kg in mouse lung tumor model with KRAS mutation, dose is tolerated in mouse; toxicology studies on-going Clinical-stage reference ERK inhibitor, GDC-0994, inhibited tumor growth about 50% at dos
Slide 18: KO-947: Rationale for Further Study
KO-947: RATIONALE FOR FURTHER STUDY IND-enabling studies ongoing Evaluating potential lead indications Development Plans Anticipated Milestones U.S. Commercial Opportunity IND submission1H 2016 Initiate Phase 1 study1H 2016 BRAF mutant malignant melanoma annual incidence: 5,000 KRAS mutant tumors an
Slide 19: Menin-MLL inhibitor program
Menin-mll inhibitor program Licensed worldwide rights from University of Michigan Chromosomal translocations of the MLL gene play a causative role in the onset, development and progression of a subset of acute leukemias Potential first-in-class program targeting the menin-MLL interaction for treatme
Slide 20: In Vivo Activity of Menin-MLL Inhibitors in Models of Disseminated Leukemia
In Vivo Activity of Menin-MLL Inhibitors in Models of disseminated leukemia Vehicle MI-503 (60 mg/kg) Transplantation with MV4;11 (MLL-AF4) Leukemic cells denoted by bioluminescence
Slide 21: Experienced management team
Experienced management team Chief Executive Officer Troy Wilson, Ph.D., J.D. Chief Scientific Officer Yi Liu, Ph.D. SVP, Chemistry and Pharm. Sciences Pingda Ren, Ph.D. Chief Medical Officer Antonio Gualberto, M.D., Ph.D. Chief Financial Officer Heidi Henson, CPA SVP and General Counsel Annette Nort
Slide 22: Board and advisors
Board and advisors President and CEO, Receptos, Inc. Faheem Hasnain Chief Financial Officer, AnaptysBio, Inc. Robert Hoffman President and CEO, Kura Oncology, Inc. Troy Wilson, Ph.D., J.D. Professor and Chairman, Dept. Cellular & Molecular Pharmacology, UCSF Kevan Shokat, Ph.D. Director Emeritus of
Slide 23: Solid Financial Foundation
SOLID FINANCIAL FOUNDATION Private Placement and Transition to Public Company $60 million raise led by EcoR1 Capital Fidelity Management & Research Company Arch Venture Partners Boxer Capital of Tavistock Life Sciences Partner Fund Management NextTech Invest Includes conversion of $7.5M convertible
Slide 24: Diverse pipeline with potential for near-term value-creating milestones
Diverse pipeline with potential for near-term value-creating milestones PROGRAM EVENT ANTICIPATED TIMING Tipifarnib Initiate Phase 2 clinical trial in PTCL Q3 2015 KO-947 IND submission 1H 2016 KO-947 Initiate Phase 1 clinical trial 1H 2016 Tipifarnib Topline data from Phase 2 clinical trial in HRAS
Slide 25: Investment summary
Investment summary Develop a diverse pipeline of targeted therapeutics for solid tumors and blood cancers Utilize precision medicine approach to identify patients most likely to benefit from treatments Strategy Development Approach Pipeline Solid Financials Fast-to-market strategies in select patien
Slide 26: Slide 26